Blair Prochnow

Blair Prochnow

Auto-generated profile, based on publicly available information

Blair Prochnow

D Department of Vaccinology and Applied Microbiology , Helmholtz Centre for Infection Research , Braunschweig , Germany

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2013 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
PRPeggy Riese
Peggy Riese
KSKai Schulze
Kai Schulze
TEThomas Ebensen
Thomas Ebensen
BPBlair Prochnow
Blair Prochnow
CGCarlos A. Guzmán
Carlos A. Guzmán
Vaccines represent the most efficient tool for preventing diseases caused by infectious pathogens. During the last century significant progress has been made in vaccine development, resulting in the eradication or control of several diseases. However, the emergence of new pathogens and the inadequate protection conferred by some existing vaccines render necessary new vaccination strategies. Newly arising immunization approaches, such as subunit vaccines and mucosal administration, make the use of novel adjuvants essential. However, only a limited number of adjuvants are available on the market. The present review is focused on vaccine adjuvants approved for human vaccines and promising candidates which are currently under development. In this regard, emerging immune stimulators and combinations are discussed, together with their strengths, limitations and regulatory framework.

15 January 2009 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
CWChristian Wahl
Christian Wahl
WMWerner Muller
Werner Muller
FLFrank Leithäuser
Frank Leithäuser
GAGuido Adler
Guido Adler
FOFranz Oswald
Franz Oswald
UWUrsula Maria Wegenka
Ursula Maria Wegenka
The recently described cytokines IL-19, IL-20, and IL-24 share structural homology with IL-10 and are therefore classified as members of the IL-10 family of cytokines. Although it has long been speculated that signaling by their heterodimeric receptor complexes (IL-20R1/IL-20R2 and IL-22R/IL-20R2) influences immunological processes, the target cells for this group of cytokines are still unclear. By generating a knockout mouse strain deficient for the common IL-20R β-chain (IL-20R2), we show that IFN-γ and IL-2 secretion is significantly elevated after stimulation of IL-20R2−/−-deficient CD8 and CD4 T cells with Con A or anti-CD3/CD28 in vitro. IL-10 secretion by activated IL-20R2−/− CD4 cells was diminished. Consistent with our in vitro results, significantly more Ag-specific CD8 IFN-γ+ and CD4 IFN-γ+ T cells developed to locally applied DNA vaccines in IL-20R2-deficient mice. In a T cell-dependent model of contact hypersensitivity, IL-20R2 knockout mice were more sensitive to the contact allergen trinitro-chloro-benzene. Thus, IL-20R2 signaling directly regulates CD8 and CD4 T cell answers in vitro and in vivo. For the first time, we provide evidence that IL-19, IL-20, and IL-24 are part of a signaling network that normally down-modulates T cell responses in mice.

1 September 2009 in Gastroenterology
Verified
Journal Article
Closed access
ASAngela Schippers
Angela Schippers
CLChristoph Leuker
Christoph Leuker
OPOliver Pabst
Oliver Pabst
AKAnnika Kochut
Annika Kochut
BPBlair Prochnow
Blair Prochnow
WMWerner Muller
Werner Muller

21 November 2007 in FEBS Letters
Verified
Journal Article
Closed access
FVFranz Vauti
Franz Vauti
BPBlair Raymond Prochnow
Blair Raymond Prochnow
EFElke Freese
Elke Freese
SRSuresh Kumar Ramasamy
Suresh Kumar Ramasamy
PRPatricia Ruiz
Patricia Ruiz
HAHans-Henning Arnold
Hans-Henning Arnold

2 February 2017 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
MAManas Akmatov
Manas Akmatov
LJLeonhard Jentsch
Leonhard Jentsch
PRPeggy Riese
Peggy Riese
MMMarcus May
Marcus May
MAMalik W. Ahmed
Malik W. Ahmed
Frank PesslerFrank Pessler
Frank Pessler
Participation in epidemiological studies has strongly declined in recent years. We examined the reasons for (non)participation in population-based health studies among participants and nonparticipants of a prospective study on influenza vaccination among the elderly. Males and females between 65 and 80 years of age (N = 5582) were randomly selected from the residents’ registration office in Hannover, Germany, and were invited to participate in a study featuring vaccination with a seasonal adjuvanted influenza vaccine (Fluad™, Novartis) including five follow-up visits (day 0, 1/3, 7, 21, 70 with respect to vaccination). A 24-item nonresponder questionnaire, including 10 items on reasons for participating in a hypothetical health study, was mailed to 1500 randomly selected nonparticipants. The same 10 items were included in the end-of-study questionnaire administered to the participants in the vaccination study (n = 200). Logistic regression analysis with backward elimination was used to identify the reasons most strongly associated with nonparticipation. Five hundred thirty-one (35%) nonparticipants and 200 participants (100%) returned the respective questionnaires. Nonparticipation was associated with a lower interest in obtaining personal health information (OR = 3.32) and a preference for less invasive (OR = 3.01) and less time-demanding (OR = 2.19) studies. Responses to other items, e.g. regarding altruistic motives, monetary compensation, general interest of the study, or study approval through ethics committee and data security authority, did not differ between participants and nonparticipants. Participation rates in health studies among elderly individuals could potentially be improved by reducing interventions and time demand, for instance by implementing methods of self-sampling and remote data collection. No. 1100359 (ClinicalTrials.gov, date of registration: 09.02.2015).

2 July 2016
Verified
Book Chapter
Closed access
PDF file
KSKai Schulze
Kai Schulze
TEThomas Ebensen
Thomas Ebensen
PRPeggy Riese
Peggy Riese
BPBlair Prochnow
Blair Prochnow
CLClaus-Michael Lehr
Claus-Michael Lehr
Carlos Alberto GuzmánCarlos Alberto Guzmán
Carlos Alberto Guzmán